AK1967 (Invobenitug also known as Procizumab)
Preclinical
AK1967 (Invobenitug also known as Procizumab) is one of 14 therapeutic programs targeting Shock. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
17 competitors in Shock
#DrugCompanyPhaseTrials
1Dobutrex
Eli LillyApproved
Intropin
PfizerApproved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Pitressin
AAultman Health Foundation
Approved
Nitrostat
VViatris Specialty LLC
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Jardiance
Boehringer IngelheimApproved
Cyklokapron
AAmring
Approved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Shock1 trial
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- 44TEEN4 Pharmaceuticals GmbH